SCHEMBL4521433

SCHEMBL4521433

CCCCOC(=O)Cc1sc2nc(Cc3ccc(Cl)c(Cl)c3)[nH]c(=O)c2c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 4/20 0.44
MAPT P10636 1/20 0.44
RNASEH1 O60930 1/20 0.44
CCNE2 O96020 1/20 0.42
CCNE1 P24864 1/20 0.42
CDK2 P24941 1/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
PIP4K2A P48426 1/20 0.41
LMNA P02545 1/20 0.39
KCNH2 Q12809 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
PDE5A O76074 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DHFR P00374 1/20 0.37
TYMS P04818 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494840 0.84 RNASEH1 (0.54) ALDH1A1KDM4EMAPTRNASEH1KMT2A
SCHEMBL4511602 0.83 HPGD (0.45) ALDH1A1KDM4EMAPTRNASEH1CCNE2
SCHEMBL4517291 0.83 RNASEH1 (0.46) ALDH1A1KDM4EMAPTRNASEH1CCNE2
SCHEMBL3491779 0.79 RNASEH1 (0.50) ALDH1A1KDM4EMAPTRNASEH1KMT2A
SCHEMBL3494138 0.78 RNASEH1 (0.52) ALDH1A1KDM4EMAPTRNASEH1KMT2A
SCHEMBL4514505 0.78 KMT2A (0.65) ALDH1A1KDM4EMAPTRNASEH1KMT2A
SCHEMBL16175762 0.76 RNASEH1 (0.54) ALDH1A1KDM4EMAPTRNASEH1KMT2A
SCHEMBL3491664 0.76 RNASEH1 (0.58) ALDH1A1KDM4EMAPTRNASEH1KMT2A
SCHEMBL21504938 0.75 KMT2A (0.58) ALDH1A1KDM4EMAPTRNASEH1KMT2A
SCHEMBL38376 0.75 RNASEH1 (0.52) ALDH1A1KDM4EMAPTRNASEH1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 ALDH1A1 2303/4885KDM4E 2859/4885MAPT 1619/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 ALDH1A1 2303/4885KDM4E 2859/4885MAPT 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.